Purpose: To evaluate the efficacy of GH in improving FAH in ISS children in a multicenter study.
Methods: A real-world observation was carried out. Children with ISS in seven hospitals in China were enrolled. The height gain standard deviation score and the height gain over the target height were evaluated.
Results: There were 344 ISS patients (217 boys and 127 girls). The baseline average age of boys and girls was 12.7 and 11.7 years, with bone age of 11.7 and 10.1 years, respectively. The baseline height SDS of boys and girls was -3.07 and -2.74, and the FAH SDS was -1.91 and -1.38, respectively. Compared with the baseline height SDS, the FAH SDS was significantly increased in both boys and girls (both P=0.0000). The FAH SDS was the highest (gain by 1.54 SD) in the ≥2y treatment course group. 218 patients (218/344, 63.4%) had an FAH SDS > -2 SD. Among these patients, girls in the 1-2y treatment course group and ≥2y group had a FAH SDS higher than TH SDS. A multivariate linear regression model was used to analyze the results, with FAH SDS as the dependent variable. It was found that the treatment course and baseline height SDS in the boys' model were statistically significant (P<0.05), whereas the baseline height SDS and baseline bone age significantly affected the girls' FAH SDS (P<0.05).
Conclusions: When GH is applied for treating ISS, a treatment course of 2 years or more can achieve better efficacy.
19 - 21 Sep 2019
European Society for Paediatric Endocrinology